Pharma BD Deal Intelligence
Mike Cola, President of Shire's Specialty Pharmaceuticals business: 'This acquisition is a strong and complementary strategic fit for Shire,' establishing a…
Shire positioned the ABH deal as the cornerstone of a regenerative medicine platform expansion beyond rare disease — analysts flagged execution risk given…
Shire took a $650M impairment and divested Dermagraft to Organogenesis after the venous-leg-ulcer trial failed and Medicare reimbursement changes 'reduced…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Shire acquired Advanced BioHealing for $750M cash to establish a regenerative medicine business unit; lead asset Dermagraft was an FDA-approved bioengineered skin substitute for diabetic foot ulcers. Closed Q3 2011.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Shire plc / Advanced BioHealing, Inc. (this deal) | 2011 | $750M | 7 |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| Shire plc / Baxalta Inc. | 2016 | $32.0B | 77 |
| Shire plc / ViroPharma Incorporated | 2013 | $4.2B | 58 |
← Browse all deals · How we score deals
More: 2011 deals · Shire plc deals · Metabolic deals